Dyadic International, Inc. (NASDAQ:DYAI) Short Interest Update

Dyadic International, Inc. (NASDAQ:DYAI) was the target of a large decrease in short interest in the month of December. As of December 31st, there was short interest totalling 121,300 shares, a decrease of 22.7% from the December 15th total of 157,000 shares. Based on an average daily trading volume, of 91,200 shares, the short-interest ratio is presently 1.3 days. Approximately 0.6% of the shares of the company are short sold.

Dyadic International Stock Down 0.6 %

DYAI stock opened at $1.56 on Thursday. Dyadic International has a twelve month low of $0.93 and a twelve month high of $2.67. The company has a quick ratio of 5.15, a current ratio of 5.15 and a debt-to-equity ratio of 1.54. The company has a market cap of $46.16 million, a PE ratio of -6.78 and a beta of 0.89. The business’s 50-day simple moving average is $1.61 and its 200 day simple moving average is $1.39.

Dyadic International (NASDAQ:DYAI) last released its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.06. The business had revenue of $1.96 million for the quarter, compared to analysts’ expectations of $1.05 million. Dyadic International had a negative return on equity of 149.16% and a negative net margin of 188.09%. During the same period in the previous year, the business posted ($0.06) earnings per share. On average, research analysts anticipate that Dyadic International will post -0.18 earnings per share for the current year.

Analyst Ratings Changes

Separately, HC Wainwright restated a “buy” rating and set a $6.00 target price on shares of Dyadic International in a research note on Thursday, November 14th.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Dyadic International stock. Chapin Davis Inc. boosted its stake in Dyadic International, Inc. (NASDAQ:DYAI) by 2.5% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 868,301 shares of the biotechnology company’s stock after buying an additional 21,000 shares during the quarter. Chapin Davis Inc. owned approximately 2.97% of Dyadic International worth $903,000 at the end of the most recent quarter. 27.95% of the stock is owned by institutional investors.

About Dyadic International

Dyadic International, Inc, a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health.